Orthocell Ltd (AU:OCC) has released an update.
Orthocell Ltd has announced its expansion into the Canadian market with the first sales of Striate+, a dental regeneration product, following recent Health Canada approval. The company is experiencing strong revenue growth, with a record $6.76 million in FY24, a 30.76% increase year-over-year, indicating successful market penetration. Orthocell, with a solid cash position and strategic partnerships, is pushing for regulatory approvals in additional markets, including Brazil and Singapore within the next 6-12 months.
For further insights into AU:OCC stock, check out TipRanks’ Stock Analysis page.